Tekturna (Aliskiren Hemifumarate) - Summary

TEKTURNA SUMMARY

Aliskiren, the active component of Tekturna ^® Tablets, is an orally active, nonpeptide, potent renin inhibitor. Aliskiren is present in Tekturna Tablets as its hemifumarate salt.

Tekturna ^® (aliskiren) is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. Use with maximal doses of ACE inhibitors has not been adequately studied.

See all Tekturna indications & dosage >>

TEKTURNA NEWS HIGHLIGHTS

Media Articles Related to Tekturna (Aliskiren)

Rasilez®, First-in-class Direct Renin Inhibitor, Provides Greater Reduction In High Blood Pressure Than ACE Inhibitor Ramipril
Source: Hypertension News From Medical News Today [2008.11.15]

Rasilez HCT®, Single-pill Combination Of Rasilez® And Diuretic, Receives Swiss Approval For The Treatment Of High Blood Pressure
Source: Hypertension News From Medical News Today [2008.11.06]

Hypertension Develops Early, Silently, In African-American Men
Source: Hypertension News From Medical News Today [2008.11.18]

FREEDOM-C Trial Of Oral Treprostinil In Pulmonary Arterial Hypertension Fails To Meet Primary Endpoint
Source: Hypertension News From Medical News Today [2008.11.18]

Hypertension In Europe: A Worrying Scenario
Source: Hypertension News From Medical News Today [2008.11.12]

more >>

Published Studies Related to Tekturna (Aliskiren)

Aliskiren combined with losartan in type 2 diabetes and nephropathy. [2008.06.05]

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. [2008.03]

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. [2007.12]

Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. [2007.11]

Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. [2007.09]

more >>

Clinical Trials Related to Tekturna (Aliskiren)

Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects. [Completed]

Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects. [Completed]

A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients [Completed]

Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension [Recruiting]

SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension [Active, not recruiting]

more >>